
Tungsten Mining plans 40,000-metre Mt Mulgine drill campaign
Tungsten Mining NL (ASX:TGN, OTCQB:TGNMF) is preparing a major reverse circulation drilling campaign at its Mt Mulgine project in Western Australia, with...
Loading news...

Tungsten Mining NL (ASX:TGN, OTCQB:TGNMF) is preparing a major reverse circulation drilling campaign at its Mt Mulgine project in Western Australia, with...

A fresh squeeze in global helium markets is sending prices sharply higher and exposing just how fragile the supply chain for the critical industrial gas has...

Elixir Energy Ltd (ASX:EXR, OTC:ELXPF) has reported strong drilling results from its Lorelle-3H appraisal well in Queensland’s Taroom Trough, recording more...

The S&P/ASX Small Ordinaries Index (ASX: XSO) closed Friday at 3,384.20, down 42.60 points (1.24%), extending its decline to 142.60 points (4.04%) over the...

10:15am: In the red US stocks kicked off Thursday’s session lower as geopolitical tensions continued to send oil prices higher. The Dow Jones fell 0.5% at...

Percheron Therapeutics Ltd (ASX:PER, OTC:PERCF) has secured acceptance of an abstract for presentation at the American Association for Cancer Research...

Percheron Therapeutics Ltd (ASX:PER, OTC:PERCF) last week outlined progress on its lead oncology asset HMBD-002, positioning the immunotherapy program to...

10:40am: Week ahead Wall Street is heading into another crowded and potentially volatile week, with investors juggling a heavy earnings calendar, a backlog...

Sally Beauty Holdings (NYSE:SBH) reported fiscal first quarter results that modestly topped Wall Street expectations, with shares rising about 4.5% in early...

Percheron Therapeutics Ltd (ASX:PER, OTC:PERCF) has closed the December 2025 quarter with its lead oncology program HMBD-002 positioned to move into phase...

London, United Kingdom--(Newsfile Corp. - November 27, 2025) - Edison issues report on Percheron Therapeutics (ASX: PER)We have refreshed our

Immunotherapy has reshaped cancer treatment over the past decade — yet its limits are becoming just as clear as its successes. Drugs that were once expected...